Objective: To evaluate the efficacy of prophylactic antibiotics in preventing infection associated with central venous catheters in preterm neonates.
Introduction
Central venous lines (CVLs) are routinely used for monitoring and the administration of total parenteral nutrition (TPN) and medications in neonatal intensive care units (NICUs) 1 A prospective cohort study on 19 000 infants admitted to NICUs, CVLs were placed in 22.5% of patients and were associated with a significant risk of systemic bacterial infection. 1 One study showed the rate of CVL-associated bacteremia to be 13 per 1000 percutaneous catheter days compared to 3 per 1000 days in infants without a CVL. 1 Bloodstream infections caused by normal skin flora result in catheter colonization, bacteremia and prolonged hospitalization. [2] [3] [4] [5] [6] Coagulase-negative-staphylococcal (CoNS) bacteremia accounts for 80% of all CVL-related bacteremia. 1, 7, 8 Other organisms associated with central catheters are Klebsiella, Enterobacter, Escherichia coli, Serratia, Citrobacter and Candida species. 1, 7, 8 Neonatal sepsis remains an important cause of morbidity and mortality in NICUs despite advances in care and the use of broad spectrum antibiotics. [9] [10] [11] [12] [13] [14] [15] Factors that have been reported to increase the incidence of catheter-related bloodstream infection (CRBSI) include low birth weight, prematurity, number of CVL days, the number of previously placed catheters and infusion of TPN.
Clearly, it is desirable to prevent CRBSI, and strategies to this end include topical skin antiseptics, antibiotic-impregnated catheters and prophylactic systemic antibiotics. This systematic review focuses on the use of prophylactic systemic antibiotics as a means to prevent CRBSI. Our primary objective was to determine the effectiveness of prophylactic antibiotics in the prevention of CVL-related bacterial infection in neonates, when the blood culture from CVL and the peripheral blood culture are positive and have similar organisms.
Methods

Identification of studies
Types of studies. This review included only randomized control trials, which studied the role of prophylactic antibiotics for the prevention of CRBSI in preterm neonates with following priori inclusion and exclusion criteria.
Types of participants. The main priori inclusion criteria for consideration of the randomized control trials were Preterm infants (<37 completed weeks) less than 1-month-old admitted to the NICU Centrally/peripherally inserted central venous catheters The main priori exclusion criteria for consideration of the randomized control trials were Neonates with renal disease Congenital malformations Catheter inserted within 48 h of life These antibiotics were compared with a placebo or with no intervention.
Outcome measures Primary
True CRBSI
In an infant with signs of sepsis, a true CRBSI was defined as the simultaneous growth of similar organism from the blood culture drawn from the central line (including percutaneous central venous catheterization (PICC) tip or hub) and the peripheral site.
Probable CRBSI In an infant with signs of sepsis, a probable CRBSI was defined by either a positive blood culture from the PICC line or hub or a negative blood culture from the peripheral site.
Secondary outcomes
Vancomycin-resistant organisms Supraventricular tachycardia, blockage of the catheter, dislodgment, thrombosis, Duration of illness Follow-up. Groups were followed-up for the duration that the catheter remained in situ.
Search strategy for identification of studies
The search strategy of the Cochrane Neonatal Review Group was used. The information was compared and all differences were resolved by consensus. In the event consensus could not be reached, a third reviewer was asked to complete the activity and resolve the disagreement.
Choice between qualitative and quantitative (meta-analysis) pooling was based on the available data and homogeneity.
Statistical analysis. The whole data were analyzed by RevMan software 4.2.8. In RevMan, heterogeneity was assessed using a w 2 -test and P-values lower than 0.05 was interpreted as statistical heterogeneity. There was no statistically significant difference among the results; therefore, a fixed effect model was used for meta-analysis.
Methodological quality
Two reviewers independently evaluated the methodological quality according to van Tulder's guidelines. 17 This instrument is designed to assess internal validity of clinical trials and should include 11 items. Trials fulfilling six or more items were considered to be high quality. It was impractical to mask the reviewers to the author, institution or journal.
Statistical analysis. Statistical analysis included relative risk (RR), risk difference (RD), number needed to treat (NNT) for dichotomous outcomes and weighted mean difference (WMD) for continuous outcomes. All estimates of treatment effects were reported with 95% CI. Studies using the same antibiotics were grouped for the analyses.
Description of studies
Three studies assessing the effects of prophylactic antibiotics versus no antibiotics, for the prevention of CRBSI were identified ( Figure 1 ). [18] [19] [20] All three studies were published as full text articles. [18] [19] [20] Authors of these studies were contacted to obtain additional relevant information. Vancomycin 18, 20 (two studies) and amoxicillin 19 (one study) were used as a prophylactic antibiotic for prevention of CRBSI.
Garland et al. 18 performed a randomized pilot trial of a vancomycin-heparin lock solution for prevention of CRBSI in neonates. A total of 134 preterm infants were eligible for the study; however, only 90 were enrolled and randomized. Two infants were lost to follow-up. Three infants were excluded from this study because a PICC line was inserted within the first 2 days of life. A total of 85 preterm infants needing PICCs were randomly assigned to have their PICC locked b.i.d. for 20 to 60 min with 0.4 ml of vancomycin-heparin lock solution (vancomycin 25 mg ml À1 ; heparin 10 IU ml À1 ) or normal saline (control). Randomization was adequate, centralized and concealed. All patients were counted during follow-up. Blood cultures were drawn from a peripheral site, PICC lines and from PICC line hubs whenever sepsis was suspected. PICC line hubs and PICC line tips for culture were also sent after removal of PICC lines. Surveillance cultures were also sent to detect vancomycin-resistant organism colonization. Toxicity due to vancomycin was also monitored by regular vancomycin drug levels on all included patients.
Spafford et al. 20 conducted a randomized, double-masked, controlled trial to determine whether vancomycin added to TPN solution infused via CVL would decrease the incidence of CRBSI. During the 15-month period of enrollment, 84 patients needed CVL placement. One patient was excluded because of poor renal function. Thirteen infants were not included because of parental refusal or the inability to contact a parent before catheter insertion. A total of 70 preterm infants (birth weight <1000 g) (35 infants in each group) were recruited during the study period. TPN was mixed with either vancomycin (25mg of vancomycin per ml) or without vancomycin, infused continuously through CVL. Randomization was performed by using sealed envelopes. In total 70 infants were randomly selected for the study, with 35 in each group. In total 52 catheters were inserted in the control group and 41 catheters were inserted in the patients receiving vancomycin (study group). Specimens from catheters were sent for culture upon removal of the catheters to monitor for a possible colonization. Adverse effects of drugs, particularly renal toxicity, were monitored by renal function tests (for example, blood urea nitrogen, creatinine) and ototoxicity was assessed by brain-stem auditory evoked potentials on all patients included in the study.
Vancomycin levels were monitored on a weekly basis. Ototoxicity is a known toxic effect of vancomycin. Diagnosis of ototoxicity was further confirmed.
Harms et al. 19 performed a randomized, controlled, sequential trial in preterm infants who underwent PICC. A total of 75 infants (median birth weight 1240 g; median age at insertion, 3 days) received prophylactic amoxicillin (100 mg per kg per day), whereas 73 infants in the control group (median birth weight, 1170 g; median age 2 days) did not receive routine prophylactic antibiotics. Infants eligible for the study were selected randomly immediately after insertion of a central venous catheter. The method of randomization was not clearly described in the study. The central venous (Silastic) catheters were inserted by a member of medical staff under an aseptic technique. One unit of heparin Potentially relevant RCTs identified and screened for retrieval (n=35) RCTs excluded without indwelling catheters or central venous line Studies were excluded because did not use an antibiotic and used other lock or flush solution (19) and included adult population (1) RCTs retrieved for more detailed evaluation (n=23)
Randomized, controlled trials with usable information by outcome (n=3) Figure 1 Flow chart depicting the selection process of studies included in the systemic review.
Catheter-related infection and neonates A Lodha et al (minimum 50 units per day) was added to each milliliter of infusate. Sepsis was monitored by bacteriological culture of fluid from the connecting hub (twice a week) and by studying inflammatory markers (leukocyte counts, ratio of immature to total neutrophils (I/T ratio), thrombocytes, C-reactive proteins (CRP)). CRBSI was assumed if there were clinical signs (for example, apnea, bradycardia, instability of temperature, feeding problems, circulatory changes, lethargy), suspicious laboratory findings (CRP>0.6 mg per 100 ml; I/T ratio>0.16) and if cultures revealed identical bacterial growth in the line tip and blood.
Methodological quality of included studies
Two studies 18,20 scored 11 on van Tulder qualitative assessment instrument, 17 and, therefore, were high quality studies. One study 19 scored 4 on van Tulder qualitative assessment instrument 17 and therefore, was lower quality study (Table 1) .
Results
Three studies were included in the final analysis (Table 1) . Due to the difference in the intervention used, we were able to combine only the two studies that used vancomycin, 18, 20 whereas the third study that used amoxicillin was reported separately. 19 The secondary outcomes in all three studies are described in Table 2 .
The efficacy of prophylactic antibiotics to prevent CRBSI in preterm infants in the NICUs was studied in all three trials. The number of patients and the duration of follow-up varied greatly between studies. The patients' characteristics were similar in both treatment and control groups.
The meta-analysis of two trials 18, 20 that used vancomycin revealed that neonates who had received vancomycin had an 87% reduction in the incidence of sepsis (RR 0.13, 95% CI 0.04 to 0.46) compared with no treatment or placebo (P ¼ 0.002) (Figure 2) . By using vancomycin the risk of infection decreased from 23 to 2.4%, with an absolute risk reduction (ARR) or RD of approximately 20% (95% CI À0.29 to À0.11) (P ¼ 0.0001), which yields an NNT equal to 5 (P ¼ 0.0001). The total duration of catheter stay and mortality were similar in both vancomycin and control groups (WMD 1.40, 95% CI À10.27 to 13.07). There was no difference in the positive culture results on removal of the catheter in both groups (RR 0.54, 95% CI 0.28 to 1.06). In Garland's study 18 , no vancomycin-resistant organisms were observed. In the Spafford study 20 the main organism isolated was coagulase-negative staphylococci (15% in control vs 0% in study). The other organisms isolated were Candida species, (2) E. coli (1), Diphtheroids (1) and Trichosporon beigelii (1). This study did not show any adverse effects due to vancomycin. The funnel plot is shown in Figure 3 . This plot did not show any publication bias.
In the amoxicillin study 19 CRBSI was not significantly different between the treatment and control groups (RR 0.40, 95% 0.12 to 1.35, P ¼ 0.14) (Figure 4) . The rate of colonization was significantly higher in the control group (RR 0.48, 95% CI 0.24 to 0.95, P ¼ 0.03). By using amoxicillin the risk of infection decreased from 3 to 0%., with an ARR or RD of approximately 3% (95% CI À0.08 to À0.01) (P ¼ 0.13). The most commonly isolated organism from the catheter tip was CoNS. In total 47% of all isolated organisms was susceptible to amoxicillin in vitro. The duration of catheterization was similar in both groups. This study did not report any serious side effects due to amoxicillin, however, thrombotic complications were observed in seven infants (9.3%) in the amoxicillin group and in two infants (2.1%) in the control group. The most likely explanation for this complication was a chance or due to intravenous injection of hyperosmolar drugs. 19 The incidence of NEC, ICH, thrombosis and death were not statistically significant between groups in both studies. 19, 20 Garland et al. 18 did not report any other morbidity such as NEC, ICH and meningitis. Secondary outcomes are shown in Table 2 .
Discussion
Central venous catheters play a vital part in the management of preterm infants in the NICU. Preterm infants need a CVL for nutrition, drug administration and monitoring. Preventive measures like prophylactic antibiotics and sterile dressings are important in avoiding CRBSI.
Only three studies [18] [19] [20] were eligible for this review. Two studies used vancomycin for prevention of CRBSI. We found that the incidence of CRBSI was reduced by 88% using vancomycin as a prophylactic antibiotic. Coagulase-negative staphylococci accounted for the majority of CRBSI in the control group in all three studies. There was a statistically significant difference in the incidence of sepsis between the groups. In 23% neonates CRBSI was due to CoNS, which was similar to other studies. 2, [21] [22] [23] [24] [25] [26] Although amoxicillin is not commonly used as a prophylactic antibiotic in routine NICU practice to prevent CRBSI, Harms et al. 19 tested it. This study 19 was underpowered and did not show any significant reduction in the incidence of CRBSI, thus, the role of amoxicillin, in the prevention of CRBSI is questionable. In addition, the excess catheter-associated clots may have been a chance finding or may be related to the injection of the hyperosmolar drug.
There were no direct adverse effects of prophylactic antibiotics on mortality or on the length of hospital stay in either study. 18, 20 Concern remains about the emergence of drug resistance in common organisms due to the use of prophylactic antibiotics. It was speculated that local antibiotic prophylaxis would promote resistance. One study 18 included in our review and another study 27 in the children used an antibiotic-containing lock solution had no relation with nosocomial colonization or the emergence of vancomycin-resistant enterococci. 28 One study 20 did not report organism resistance to antibiotics. In the absence of sufficient evidence to justify their use, prophylactic antibiotics have not become routine practice in modern NICUs. 16 Because of the small number of patients and few studies that contributed data for the current meta-analysis, the overall picture emerging is still unconvincing.
In an effort to reduce the incidence of CRBSI, various interventions have been used. These include different antibacterial skin preparations, the type of dressing at the site of catheter insertion, experience of staff members, catheter material, single versus double lumen catheters and catheters with antiseptic or antibiotic coatings. 29 Better prospective studies of sufficient size, which will address all potential risk factors, including insertion site and hub colonization, insertion technique and details of follow-up care, would enhance our understanding of the pathogenesis of CRBSI and guide efforts to develop more effective strategies for prevention.
Despite the broad search strategies employed in this systematic review, we found only three RCTs, all of them published in English and two studies were rated as high methodological quality. It is possible that we might have overlooked some trials or that there is some publication bias. We tried to avoid bias in the execution of this review by having two authors perform the study selection and data extraction. Role of prophylactic antifungal for catheterrelated fungal infection will require a separate systematic review with inclusion of all randomized controlled trials. Figure 2 The role of prophylactic vancomycin versus control for prevention of catheter-related sepsis in neonates.
Catheter-related infection and neonates A Lodha et al Implications for practice Insufficient evidence exists to recommend routine use of vancomycin in extremely low birth weight infants with central venous catheters. Prophylactic vancomycin, but not amoxicillin, is effective for prevention of CRBSI and related morbidity, in preterm infants in NICUs.
Future research
(1) More well-designed controlled trials evaluating the effectiveness of prophylactic antibiotics and their potential risk for the emergence of resistance to the organism need to be carried out. These trials should assess both short-and long- Figure 3 Funnel plot to assess publication bias. Each circle represents one study. Publication bias was not detected. Test for overall effect: Z = 1.47 (P = 0.14)
0.001 0.01 1 10 100 1000 0.1 Favours Amoxicillin Favours Control Figure 4 The role of prophylatic amoxicillin versus control for prevention of catheter-related sepsis in neonates.
Catheter-related infection and neonates
A Lodha et al term physiological, clinical and neurodevelopmental outcomes (because of potential ototoxicity and nephrotoxicity) in these neonates. (2) A cost-effectiveness evaluation of the use of vancomycin is required.
